Literature DB >> 20233467

The pathology of hereditary breast cancer.

Emiliano Honrado1, Javier Benítez, José Palacios.   

Abstract

Several studies have demonstrated that familial breast cancers associated with BRCA1 or BRCA2 germline mutations differ in their morphological and immunohistochemical characteristics. Cancers associated with BRCA1 are poorly differentiated infiltrating ductal carcinomas (IDCs) with higher mitotic counts and pleomorphism and less tubule formation than sporadic tumours. In addition, more cases with the morphological features of typical or atypical medullary carcinoma are seen in these patients. Breast carcinomas from BRCA2 mutation carriers tend to be of higher grade than sporadic age-matched controls. Regarding immunophenotypic features. BRCA1 tumours have been found to be more frequently oestrogen receptor- (ER) and progesterone receptor-(PR) negative, and p53-positive than age-matched controls, whereas these differences are not usually found in BRCA2-associated tumours. A higher frequency and unusual location of p53 mutations have been described in BRCA1/2 carcinomas. Furthermore, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER-2 expression. Recent studies have shown that most BRCA1 carcinomas belong to the basal cell phenotype, a subtype of high grade, highly proliferating ER/HER2-negative breast carcinoma characterized by the expression of basal or myoepithelial markers, such as basal keratins, P-cadherin, EGFR, etc. This phenotype occurs with a higher incidence in BRCA1 tumours than in sporadic carcinomas and is rarely found in BRCA2 carcinomas. Hereditary carcinomas not attributable to BRCA1/2 mutations have phenotypic similarities with BRCA2 tumours, but tend to be of lesser grade and lower proliferation index. The pathological features of hereditary breast cancer can drive specific treatment and influence the process of mutation screening.

Entities:  

Year:  2004        PMID: 20233467      PMCID: PMC4392521          DOI: 10.1186/1897-4287-2-3-131

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


  69 in total

1.  Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.

Authors:  Miguel de la Hoya; Ana Osorio; Javier Godino; Sara Sulleiro; Alicia Tosar; Pedro Perez-Segura; Cristina Fernandez; Raquel Rodríguez; Eduardo Díaz-Rubio; Javier Benítez; Peter Devilee; Trinidad Caldés
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

2.  Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.

Authors:  P O Chappuis; V Nethercot; W D Foulkes
Journal:  Semin Surg Oncol       Date:  2000-06

Review 3.  HER-2/neu (c-erb-B2) gene and protein in breast cancer.

Authors:  J S Ross; J A Fletcher
Journal:  Am J Clin Pathol       Date:  1999-07       Impact factor: 2.493

Review 4.  The pathology of familial breast cancer: Morphological aspects.

Authors:  S R Lakhani
Journal:  Breast Cancer Res       Date:  1999-10-27       Impact factor: 6.466

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

Review 6.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

Authors:  Robert Clarke; Minetta C Liu; Kerrie B Bouker; Zhiping Gu; Richard Y Lee; Yuelin Zhu; Todd C Skaar; Bianca Gomez; Kerry O'Brien; Yue Wang; Leena A Hilakivi-Clarke
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

7.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.

Authors:  M R Stratton; D Ford; S Neuhasen; S Seal; R Wooster; L S Friedman; M C King; V Egilsson; P Devilee; R McManus
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

8.  Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.

Authors:  Noah D Kauff; Edi Brogi; Lauren Scheuer; Dorothy R Pathak; Patrick I Borgen; Clifford A Hudis; Kenneth Offit; Mark E Robson
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Authors:  William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

10.  Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue.

Authors:  Peter T Simpson; Theodora Gale; Jorge S Reis-Filho; Chris Jones; Suzanne Parry; Dawn Steele; Antonio Cossu; Mario Budroni; Giuseppe Palmieri; Sunil R Lakhani
Journal:  J Pathol       Date:  2004-03       Impact factor: 7.996

View more
  7 in total

1.  BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association.

Authors:  Julie Waisbren; Regina Uthe; Kalliopi Siziopikou; Virginia Kaklamani
Journal:  BMJ Case Rep       Date:  2015-07-06

2.  A common missense variant in BRCA2 predisposes to early onset breast cancer.

Authors:  Bohdan Górski; Steven A Narod; Jan Lubinski
Journal:  Breast Cancer Res       Date:  2005-10-24       Impact factor: 6.466

Review 3.  Hereditary breast cancer: clinical, pathological and molecular characteristics.

Authors:  Martin J Larsen; Mads Thomassen; Anne-Marie Gerdes; Torben A Kruse
Journal:  Breast Cancer (Auckl)       Date:  2014-10-15

4.  Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.

Authors:  Ieva Sadzevičienė; Sonata Jarmalaitė; Justinas Besusparis; Olga Liaugaudienė; Jolita Asadauskienė; Birutė Brasiūnienė; Ilona Kulikienė; Rasa Sabaliauskaitė
Journal:  Medicina (Kaunas)       Date:  2020-03-10       Impact factor: 2.430

5.  Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.

Authors:  Maria M Litwiniuk; Krzysztof Roznowski; Violetta Filas; Dariusz D Godlewski; Małgorzata Stawicka; Remigiusz Kaleta; Jan Breborowicz
Journal:  BMC Cancer       Date:  2008-04-13       Impact factor: 4.430

6.  Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer.

Authors:  Andrea Zapater-Moros; Angelo Gámez-Pozo; Guillermo Prado-Vázquez; Lucía Trilla-Fuertes; Jorge M Arevalillo; Mariana Díaz-Almirón; Hilario Navarro; Paloma Maín; Jaime Feliú; Pilar Zamora; Enrique Espinosa; Juan Ángel Fresno Vara
Journal:  Oncotarget       Date:  2018-06-12

7.  miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.

Authors:  Danielle Pessôa-Pereira; Adriane Feijó Evangelista; Rhafaela Lima Causin; René Aloisio da Costa Vieira; Lucas Faria Abrahão-Machado; Iara Viana Vidigal Santana; Vinicius Duval da Silva; Karen Cristina Borba de Souza; Renato José de Oliveira-Silva; Gabriela Carvalho Fernandes; Rui Manuel Reis; Edenir Inêz Palmero; Márcia Maria Chiquitelli Marques
Journal:  BMC Cancer       Date:  2020-02-22       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.